TCRX
USDTScan Therapeutics Inc. Common Stock
$1.120-0.050 (-4.274%)
Prix en Temps Réel
Healthcare
Biotechnologie
États-Unis
Graphique des Prix
Loading Chart...
Métriques Clés
Métriques de Marché
Ouverture
$1.170
Haut
$1.250
Bas
$1.080
Volume
0.81M
Fondamentaux de l'Entreprise
Capitalisation Boursière
63.6M
Industrie
Biotechnologie
Pays
United States
Statistiques de Trading
Volume Moyen
0.51M
Bourse
NGM
Devise
USD
Intervalle sur 52 Semaines
Bas $1.02Actuel $1.120Haut $6.225
Actualités Connexes
Analyst Upgrades
BTIG Downgrades TScan Therapeutics to Neutral
BTIG analyst Justin Zelin downgrades TScan Therapeutics from Buy to Neutral.
Voir plus
Analyst Upgrades
Needham Maintains Buy on TScan Therapeutics, Lowers Price Target to $6
Needham analyst Gil Blum maintains TScan Therapeutics with a Buy and lowers the price target from $9 to $6.
Voir plus
GlobeNewswire
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritize heme development;
Voir plus
Actions Connexes
Restez Informé
Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.